Monika Fischer, MD, MS, FACG
Indiana University Health, IU School of Medicine
In person only
Upon completion of this activity, participants will be able to:
1. Distinguish between C. diff colonization and C. diff infection
2. Discuss recommended management of recurrent and fulminant C. difficile infection
3. Elaborate on the different options of gut microbiota restoration therapy
Disclosure of Financial Interest Summary
All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.
Monika Fischer, MD, Indiana University Health, IU School of Medicine, has served as an advisory board member for Johnson & Johnson and Eli Lilly. She has served as a chair for DSMB for Criscot and is currently a lecturer on non-branded topics for Johnson & Johnson.
All of the relevant financial relationships listed for these individuals have been mitigated.
The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.
Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
- 1.00 AMA PRA Category 1 Credit™
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This Enduring activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
- 1.00 ParticipationUK Healthcare CECentral certifies this activity for 1.00 hour(s) of participation.